Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
Cancers · 01.06.2026 · 18 (11) · 1800
DOI: 10.3390/cancers18111800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.06.2026. Verfasst von Tasuku Nakabori und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Although thermal ablation is an established curative treatment for early-stage hepatocellular carcinoma (HCC), local tumor progression (LTP) after ablation remains a clinically important issue. In advanced-stage HCC treated with immunotherapy, ablation is increasingly performed concurrently with atezolizumab plus bevacizumab (atezo/bev). However, evidence regarding its clinical outcome is limited. This study aimed to evaluate the association between concurrent atezo/bev and LTP after ablation.
Methods
This retrospective study included 467 ablated tumors from 376 treatment courses. Tumors were classified into two groups according to atezo/bev administration status. The cumulative incidence of LTP was compared between the two groups. Factors associated with LTP and ablation-related complications were also assessed.
Results
Twenty-five tumors were ablated during atezo/bev treatment in 17 treatment courses (ablation + atezo/bev group), whereas 442 tumors were ablated without concurrent atezo/bev in 359 treatment courses (ablation-alone group). The cumulative incidence of LTP was significantly lower in the ablation + atezo/bev group than in the ablation-alone group (p = 0.031). In the multivariable analysis, ongoing atezo/bev treatment was independently associated with a reduced risk of LTP (hazard ratio, 0.124; p = 0.015). No significant differences in ablation procedure-related complications were observed between the two groups.
Conclusions
Thermal ablation during atezo/bev treatment was associated with a reduced risk of LTP without an apparent increase in procedure-related complications. These findings suggest that concurrent administration of atezo/bev may be associated with improved local tumor control after ablation, supporting the feasibility of ablation as part of multidisciplinary treatment strategies for advanced-stage HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
- Cancer Control Center, Osaka International Cancer Institute, Osaka 541-8567, Japan.
ORCID-Profile: Tasuku Nakabori, Jun Murata, Makiko Urabe, Ryoji Takada, Toshitaka Morishima, Minoru Shigekawa
Zitieren
APA
Nakabori, T., Mukai, K., Miyanaga, T., Takiyama, H., Sekiya, K., Kinomoto, T., Masumoto, T., Murata, J., Urabe, M., Kai, Y., Takada, R., Morishima, T., Shigekawa, M., & Ohkawa, K. (2026). Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers, 18(11), 1800. https://doi.org/10.3390/cancers18111800
Vancouver
Nakabori T, Mukai K, Miyanaga T, Takiyama H, Sekiya K, Kinomoto T, et al. Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers. 2026;18(11):1800. doi:10.3390/cancers18111800
BibTeX
@article{Nakabori2026,
author = {Nakabori, Tasuku and Mukai, Kaori and Miyanaga, Taku and Takiyama, Hiroki and Sekiya, Keita and Kinomoto, Takumi and Masumoto, Takanori and Murata, Jun and Urabe, Makiko and Kai, Yugo and Takada, Ryoji and Morishima, Toshitaka and Shigekawa, Minoru and Ohkawa, Kazuyoshi},
title = {Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1800},
doi = {10.3390/cancers18111800}
}
EUVIMED